Research programme: AXL receptor tyrosine kinase inhibitors - Arcus Biosciences
Alternative Names: AXL inhibitors - Arcus BiosciencesLatest Information Update: 28 Jan 2024
At a glance
- Originator Arcus Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for research development in Cancer in USA
- 31 Dec 2019 Early research in Cancer in USA (unspecified route)